INTRODUCTION
Microarray studies have identified gene expression signatures associated with distinct clinical subtypes of leukemia. 1 In studies of both pediatric and adult acute lymphoblastic leukemia (ALL), patients can be classified according to specific gene expression profiles. [2] [3] [4] [5] [6] [7] [8] [9] [10] Characteristic signatures, for example, those identified in acute myeloid leukemia (AML) subtypes with t(15;17), t(8;21), inv (16) , or t(11q23)/ MLL, have been confirmed not only with different DNA oligonucleotide microarray designs, 11,12 but also by using a principally different microarray technology. 13 Furthermore, gene expression analyses of nearly 1,000 patients led to the discovery of distinct expression signatures, not only specific among adult acute and chronic leukemia subtypes, but also in comparison to nonleukemia and healthy bone marrow specimens.
14 Because microarray assays can analyze the expression of multiple genes in parallel, they have been proposed as a robust test method for diagnostic usage in a clinical laboratory. However, published data in this area have been derived from relatively small, single-center studies involving archival samples. Here, we report results from 3,334 patients who were analyzed as part of an international study group formed around the European LeukemiaNet (ELN) in 11 laboratories across three continents (seven from the ELN, three from the United States, and one in Singapore). The collaborative Microarray Innovations in Leukemia (MILE) study program was designed to assess the clinical accuracy of gene expression profiles (compared with current routine diagnostic work-up) of 16 acute and chronic leukemia subclasses, myelodysplastic syndromes (MDSs), and a so-called "none of the target classes" control group that included nonmalignant disorders and normal bone marrow.
METHODS

Study Design
There were two stages in the MILE research study: a retrospective biomarker discovery phase (stage I) using commercially available wholegenome microarrays (HG-U133 Plus 2.0; Affymetrix, Santa Clara, CA) and an independent validation phase (stage II) that was performed in a prospective manner using a newly designed custom chip (AmpliChip Leukemia; Roche Molecular Systems, Pleasanton, CA). Before each stage of the study, designated laboratory operators at each site were trained on the corresponding sample preparation protocol and had demonstrated proficiency in the technology. 15 The individual steps of the sample preparation workflow are available online. All samples in this study were obtained from untreated patients at the time of diagnosis. Cells used for microarray analysis were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. The study design adhered to the tenets of the Declaration of Helsinki and was approved by the ethics committees of the participating institutions before its initiation. The sponsor collected the anonymized patient data and performed the final statistical analysis. All authors had full access to both the primary local microarray data and the final analysis.
Microarray Data Preprocessing and Exploratory Analyses
Data preprocessing included a summarization and quantile normalization step to generate probe set level signal intensities for each microarray experiment and was performed as previously described. 16 Data visualization and exploratory analyses were performed with Partek Genomics Suite software version 6.3 (Partek, St Louis, MO) and R software version 2.5.1 (http:// www.r-project.org), including the Affy, MADE4, and Heatplus packages.
17 A margin tree graph was generated following a method previously established in the use of high-dimensional classification of cancer microarray data. 18 The margin tree is learned in an unbiased manner and emerges naturally in a mathematical procedure. All microarray raw data were deposited in National Center for Biotechnology Information's Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) under series accession number GSE13204.
19
Custom Chip Design
The AmpliChip Leukemia research microarray was specifically customized for the classification of leukemias. 20 The chip contained 1,480 distinct probe sets with 11-m feature size. The source of the probe set design was based on the commercially available Affymetrix HG-U133 Plus 2.0 microarray. One thousand four hundred fifty-seven probe sets were used for generating normalized signal intensities of disease-related genes, and 23 probe sets interrogated control sequences and housekeeping genes. Three hundred ninety-eight probe sets were tiled in triplets to increase the robustness of the algorithm performance.
Algorithm Training for Classification Analysis
For multiclass classification, an all-pairwise approach was performed using trimmed mean of differences between perfect match and mismatch intensities with quantile normalization (DQN) signals. 16 For 18 classes, there were 153 distinct class pairs. For every class pair, a linear binary classifier was formed with support vector machines. 21, 22 For this classifier, n was the number of used probe sets. The classifier for class pair (i, j) (i Ͻ j) consisted of (n ϩ NOTE. Two thousand ninety-six high-quality analyses were performed by 11 different study centers from seven countries across three continents. Eighteen diagnostic gold standard categories are given by their class subtype labels of C1 to C18 and are listed for each participating laboratory (laboratories 1 to 11). Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; MLL, myeloid/lymphoid or mixed-lineage leukemia; pre, precursor; c-ALL, childhood acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome.
class with the maximal vote, the call was this particular class. If there was a tie of two or more classes with the maximal vote, an indeterminable call was assigned. The step of probe set selection was included in every cross-validation run and was performed to select the top 100 differentially expressed probe sets with the maximal absolute values of t statistic for every class pair. Subsequently, the union of the selected probe sets of all class pairs was used for every binary classifier.
RESULTS
Marker Discovery Phase Using Whole-Genome Microarrays
During stage I of the study, 2,143 whole-genome microarray analyses were performed. Each center had previously diagnosed the samples as part of their daily routine diagnostic work-up, using their local gold standard diagnostic methods, including cytomorphology, immunophenotyping, cytogenetics, and other molecular genetic tests. Each specimen then was assigned based on these previous diagnostic test reports to one of the 18 MILE study categories (C1 to C18) for microarray analysis. Seventeen classes had been selected as representing standard subclasses of acute and chronic leukemias, as well as MDS. Class 18 included healthy bone marrow specimens and nonleukemia conditions, such as megaloblastic anemia, hemolysis, iron deficiency, or idiopathic thrombocytopenic purpura, and was considered to be none of the target classes.
Despite strict quality criteria, 47 samples (2.2%) had to be excluded as a result of low technical quality of the gene expression profiles. The remaining 2,096 samples are listed in Table 1 . The samples were not equally distributed among the participating laboratories but were variably contributed depending on each center's expertise (eg, center 10 included chronic lymphocytic leukemia [CLL] specimens and center 7 analyzed cases of pediatric leukemias). Consistent with the actual incidence of the respective categories, lower sample numbers were submitted for certain uncommon subtypes, including mature B-cell ALL with t(8;14) (C1) and AML with inv(16)/t(16;16) (C11). All other classes comprised more than 30 samples each (range, 36 to 448 samples).
Several approaches were selected to perform exploratory data analyses. First, supervised hierarchical clustering was performed to confirm whether the selected classes would indeed harbor distinct gene expression signatures for the 2,096 whole-genome gene expression profiles. Strong differences were observed in the respective signatures for classes C1 to C18 (Fig 1) .
Next, a method developed by Tibshirani and Hastie, 18 established for high-dimensional classification of cancer microarray data, was applied. This method not only produces a classifier, but also gives output graphs, so-called margin trees, that indicate the relatedness of different disease entities. 18 A hierarchical data tree applied to our data set of 2,096 samples is shown in Figure 2 , where two major branches can be observed, one that contains mainly the B-lineage ALL categories and a second larger branch that contains the myeloid and chronic leukemias. MDS samples and nonleukemia specimens were also located in this larger branch. The binary decision tree and the hierarchical relationship among the classes can be interpreted in a top-down manner and demonstrated a meaningful organization of the 16 leukemia classes and MDS on the basis of their respective gene expression signatures.
The series of 1,292 acute leukemia samples represented in the stage I cohort were further evaluated for gene signatures that would serve as a so-called virtual immunophenotype. Fourteen distinct types of acute leukemias (C1 to C14) are displayed in a heat map of the genes encoding 21 differentiation antigens routinely used for flow cytometry (Fig 3A) . For each of the three major lineages involved in leukemia (B Class:
Supervised hierarchical clustering. The exploratory whole-genome clustering analysis was performed for all classes (C1 to C18 in ascending order) including 2,096 samples from stage I. For every class pair, the top 100 differentially expressed probes sets with the largest absolute values of t statistic were selected. The union of these sets contained 3,556 probe sets used in the clustering.
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www.jco.org cells, T cells, and myeloid cells), distinct clusters were observed based on the gene expression signature of the corresponding antigens. Subtype-specific patterns were identifiable, for example, the low expression of HLA-DR ␣ and ␥ antigens in AML with t(15;17) (C10). Such subtype-specific patterns became even more obvious when virtual immunophenotype data were represented as a series of individual box plots for each of the 14 classes of acute leukemias (Fig 3B) .
Algorithm Training for Classification Analysis
The classification performance of retrospective samples of stage I was investigated next by developing a prediction algorithm based on linear discriminant classification. To estimate the performance of the classifiers, three independent 30-fold cross-validations were used. For every possible pair of comparisons between the 18 distinct classes, the top 100 probe sets with the largest absolute values of t statistics were Margin tree classification is a supervised multiclass support vector machine classification method. 18 The margin tree program was applied to the stage I data set of 2,096 samples, characterized by their 18 class subtype labels (C1 to C18), and was based on 54,630 probe sets. B-ALL, B-cell acute lymphoblastic leukemia; MLL, myeloid/lymphoid or mixed-lineage leukemia; pre, precursor; c-ALL, childhood acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; kt., karyotype; abn., abnormality; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome. selected. The union of all selected probe sets was then used for subsequent classification of all class pairs.
When all 2,096 samples from stage I were included, the classification analysis of their whole-genome gene expression profiles demonstrated that overall, in 92.2% of samples, the gene expression classification was concordant with the initial gold-standard diagnosis (99.6% specimens with a unique call). This means that a small number of samples received indeterminable calls as a result of ties of majority votes of the classifier (Table 2 ). In seven of the 18 classes, the concordance was Ն 94.6%. As detailed in the confusion matrix, lower sensitivities in predicting leukemia types were observed, in particular, for classes C1, C7, C8, C12, and C14. This can largely be explained by the biologic heterogeneity within the class and the lack of standardized gold-standard definitions. However, it is notable that all analyzed classes showed specificities greater than 98.1% and that, overall, all 18 analyzed classes could be predicted with a median sensitivity of 92.1% and a median specificity of 99.7%.
Classification Algorithm Testing on an Independent Patient Cohort
After completion of stage I, the participating laboratories prospectively collected 1,191 samples as an independent validation cohort. Similar to stage I, only samples were included where a full gold standard diagnostic work-up had been completed by the laboratories so that each specimen would be grouped into one of the 18 study classes before microarray analysis. Experiments were performed using a standardized procedure and a customized chip, the AmpliChip Leukemia microarray. Of the 1,191 stage II gene expression profiles, 1,152 (96.7%) passed the quality criteria and were further processed for microarray classification. When using a prediction model, trained on the whole-genome gene expression profiles from stage I, the overall accuracy for all 18 classes of this independent test cohort using the custom chip was 88.1% (overall call rate, 99.6%). Similar to the stage I data set, miscalls were predominantly observed for the interface of C7/C8 in ALL and in the MDS-AML continuum. The predicted accuracies for CLL, chronic myelogenous leukemia, and MDS in stage II were 98.7%, 93.0%, and 81.5%, respectively.
When focused on an acute leukemia-type diagnostic algorithm, the overall prediction accuracy for all called samples markedly increased to 91.5% (overall call rate, 98.1%). As shown by the confusion matrix in Table 3 , 100% correct predictions were observed for five leukemia types (C1, C2, C6, C9, and C11), each of which represented leukemias with discrete disease-defining fusion genes. Lower accuracies were observed for the interface of C7/C8 in ALL, as well as for more intrinsically heterogeneous subtypes such as C12 and C14 in AML. Nonetheless, eight of the 14 represented acute leukemia types were concordant with the gold standard in Ն 95.0% of the analyses. When summarized over all acute leukemia subtypes, this focused classification scheme resulted in a 95.6% median sensitivity and a 99.8% median specificity for the eight ALL and six AML classes included in the classifier (C1 to C14, n ϭ 693). This result reinforces the strength of microarray technology, which offers high positive 
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prediction accuracy based on a standardized, robust, and objective molecular assay. During the process of clarifying discrepant results (ie, comparing microarray classifier predictions against the gold-standard diagnoses submitted to the study database), in 51 (7.4%) of 693 acute leukemia samples, discrepancies could be resolved. A first category of 22 (43%) of 51 discrepant samples were explained either because of erroneous entries into case report forms or wrong sample labels (n ϭ 13, 25%) or Specimens  C1 C2  C3  C4  C5 C6 C7  C8  C9 C10 C11 C12 C13  C14  C15  C16  C17  C18 C1/GS 9. Specimens  C1 C2  C3  C4  C5  C6  C7  C8  C9 C10 C11 C12 C13 C14 C1/GS 4 because the respective diagnoses were revised after central independent expert review of karyotypes using the definition of AML with complex aberrant karyotypes from Schoch et al 23 (n ϭ 9, 18%). A second category of 29 (57%) of 51 discrepant samples could be interpreted as samples in which the chip-based prediction had outperformed the laboratories' own gold standard diagnostic result (overall, 29 of 693 samples; 4.2%). These samples were split between specimens in which subsequent retesting of leftover material confirmed the predicted acute leukemia subtype as classified by the microarray (n ϭ 14) and specimens in which re-evaluation of initial diagnostic reports including morphology or DNA index values led to the confirmation of the microarray classification result (n ϭ 15). More detailed information on the discrepant results analyses performed on these samples is available online (Appendix Tables A1-A3 and Figures A1-A4 , online only).
DISCUSSION
In 2005, the International MILE Study Group was formed around the ELN (Gene Expression Profiling Working Group) in 11 laboratories across three continents. In two stages, the clinical accuracy of gene expression profiles of 16 acute and chronic leukemia subclasses, MDS, and a so-called "none of the target classes" control group was compared with current routine diagnostic work-up in 3,334 patients. Gold standard diagnostic methods were not standardized between centers. Each center integrated the available results from their own laboratory workflow and assigned each sample into one of the 18 MILE study microarray categories.
In stage I of the study, only 2.2% of samples failed the strict quality criteria, leaving 2,096 of 2,143 samples to be used in the training of a robust diagnostic classification algorithm. As demonstrated by various exploratory data analyses, each of the 18 diagnostic categories was characterized by a specific underlying gene expression program. The accuracy of this training cohort was estimated by cross-validation and was 92.2% for the 18 classes (median specificity, 99.7%). In seven of the 18 classes, the concordance was Ն 94.6%. A high prediction precision of 100% was observed, in particular, for the group of acute leukemias with specific chromosomal aberrations [eg, as demonstrated for pro-B-ALL with t(11q23)/MLL or the core binding factor leukemias AML with t(8;21) or AML with inv(16)/t(16;16)]. Lower sensitivities were seen in entities with biologic heterogeneity within the class (eg, AML with a complex aberrant karyotype [74.8%] or ALL with a hyperdiploid karyotype [75.8%]). However, it is notable that all analyzed classes showed specificities greater than 98.1% and that, overall, all 18 analyzed classes could be predicted with a median sensitivity of 92.1% and a median specificity of 99.7%. Thus, in terms of sensitivity and specificity, the gene expression results alone compared favorably with the laboratories' own gold-standard classification.
The potential clinical utility of microarray-based diagnostics was then validated in stage II including another 1,152 patients, a cohort that represented an independent and blinded validation set for the classification algorithms developed in stage I. Overall, in stage II, the observed accuracy of the classifier prediction across all 18 classes was 88.1%. The accuracy increased to 91.5% when focused on acute leukemias, representing all 14 distinct classes. In eight of the 14 represented acute leukemia classes, microarray diagnoses were concordant with the gold standard diagnoses in Ն 95.0% of the analyses.
To our knowledge, this is thus far the largest gene expression microarray profiling study in hematology and oncology, and it clearly underlines the robust performance of this method and demonstrates the possibility of completely standardized laboratory procedures combined with sophisticated data algorithms. This is in contrast to other, far more subjective methods routinely used for leukemia diagnosis today, such as cytomorphology and metaphase cytogenetics. The next step would now be an objective and unbiased discussion on how to position microarray technology in a routine diagnostic workflow and whether it is suitable to helpfully support or even replace some of the existing gold-standard techniques. For example, an array-based test cannot, in all cases, replace multiparameter flow cytometry or reverse transcriptase polymerase chain reaction-based detection of molecular fusion genes, which is routinely applied to define the starting point for clinically relevant detection of minimal residual disease. 24, 25 In one possible scenario, one could restrict the microarray technique to the classification of acute leukemias because CLL and chronic myelogenous leukemia are readily diagnosed by standard immunophenotyping, cytogenetics, and molecular tests. An acute leukemia classification microarray may then have utility in patients for whom a conventional cytogenetic analysis is not available, either because of no analyzable mitoses or poor quality of banded chromosomes.
26,27
Although our study concept had to define up front the most necessary leukemia entities and not all recurrent cytogenetic subtypes according to the new WHO classification of 2008 28 were represented by the actual data set, most subtypes with current clinical relevance are covered. As a further intended use, this microarray technique may also serve to classify leukemia in developing countries that currently lack expertise to perform the current labor-intensive and sophisticated diagnostic approaches.
Finally, the investigators of the MILE study submitted their gene expression database to the public domain (Gene Expression Omnibus Accession No. GSE13204) to foster research elucidating the molecular understanding of leukemias. Future refinements need to include additional signatures for prognostically important subsets of patients with AML with normal cytogenetics. 12,13,29,30 Such signatures have already been tentatively identified by a number of groups.
31-37 Microarray analysis can even be applied to investigate expression signatures of other novel markers such as WT1, 38 detect a specific pattern for RUNX1-mutated AML, 39 and discover predictive signatures for response to both currently used and novel targeted treatment regimens. 
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